{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:26:34Z","timestamp":1785486394668,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13300-026-01877-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:30:58Z","timestamp":1780133458000},"page":"1027-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study"],"prefix":"10.1007","volume":"17","author":[{"given":"Noriyuki","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6137-5493","authenticated-orcid":false,"given":"Makoto","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Seino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munenori","family":"Hiromura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemasa","family":"Omachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Takehana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michishige","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaku","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho-ichi","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"1877_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"1877_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"1877_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"1877_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"1877_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1877_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"1877_CR7","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48:S181-206.","journal-title":"Diabetes Care"},{"key":"1877_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740\u201356.","journal-title":"Cell Metab"},{"key":"1877_CR9","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180\u201393.","journal-title":"Lancet"},{"key":"1877_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"1877_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with Dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:623\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1877_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:634\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1877_CR13","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus Dulaglutide in type 2 diabetes. N Engl J Med. 2025;393:2409\u201320.","journal-title":"N Engl J Med"},{"key":"1877_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583\u201398.","journal-title":"Lancet"},{"key":"1877_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811\u201324.","journal-title":"Lancet"},{"key":"1877_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327:534\u201345.","journal-title":"JAMA"},{"key":"1877_CR17","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1111\/dom.15934","volume":"26","author":"MS Kelly","year":"2024","unstructured":"Kelly MS, Scopelliti EM, Goodson KE, Lo CM, Nguyen HX, Simon B. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2024;26:5661\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1877_CR18","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1111\/dom.15680","volume":"26","author":"A Buckley","year":"2024","unstructured":"Buckley A, Suliman S, Allum M, et al. Real-world use of tirzepatide in the treatment of type 2 diabetes in an Arab population. Diabetes Obes Metab. 2024;26:3381\u201391.","journal-title":"Diabetes Obes Metab"},{"key":"1877_CR19","doi-asserted-by":"publisher","first-page":"108779","DOI":"10.1016\/j.jdiacomp.2024.108779","volume":"38","author":"T Suzuki","year":"2024","unstructured":"Suzuki T, Sato T, Tanaka M, et al. Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus. J Diabetes Complications. 2024;38:108779.","journal-title":"J Diabetes Complications"},{"key":"1877_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153\u201365. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.004.","journal-title":"Cell Metab"},{"key":"1877_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/dom.12702","volume":"18","author":"C Wysham","year":"2016","unstructured":"Wysham C, Guerci B, D\u2019Alessio D, Jia N, Botros FT. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1138\u201342.","journal-title":"Diabetes Obes Metab"},{"key":"1877_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/jpm12030424","volume":"12","author":"A Kyriakidou","year":"2022","unstructured":"Kyriakidou A, Kyriazou AV, Koufakis T, et al. Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes. J Pers Med. 2022;12:424.","journal-title":"J Pers Med"},{"key":"1877_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10:393\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1877_CR24","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352\u20135.","journal-title":"Diabetes Care"},{"key":"1877_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839\u201348.","journal-title":"N Engl J Med"},{"key":"1877_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"1877_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:774\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1877_CR28","doi-asserted-by":"publisher","first-page":"204201882513782","DOI":"10.1177\/20420188251378216","volume":"16","author":"Y Oe","year":"2025","unstructured":"Oe Y, Nomoto H, Cho KY, et al. Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study. Ther Adv Endocrinol Metab. 2025;16:20420188251378216.","journal-title":"Ther Adv Endocrinol Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01877-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:07:53Z","timestamp":1784624873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01877-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01877-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Makoto Ohara has received lecture fees from Eli Lilly Japan K.K. Munenori Hiromura has received lecture fees from Eli Lilly Japan K.K. Yusaku Mori holds an endowed chair funded by Nippon Boehringer Ingelheim Co., Ltd. Sho-ichi Yamagishi has received lecture fees from Bayer Yakuhin, Ltd., Kowa Company, Ltd., and Novo Nordisk Pharma, Ltd. Noriyuki Takahashi, Hiroki Yokoyama, Hiroaki Seino, Shutaro Ozawa, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Ayako Ohara, Shunichiro Irie, Naoya Osaka, Michishige Terasaki, Aya Yoshihara, and Tomoyasu Fukui have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board (Ethics Committee) of Showa Medical University (approval No. 2024-200-B). Informed consent was waived due to the retrospective, non-interventional design. An opt-out approach was used: study information was publicly disclosed (institutional website and\/or notice boards at each participating site), and patients could decline participation by requesting that their clinical information (existing medical record data) not be used for research. Upon such request, the patient\u2019s data were excluded from the analysis. Opting out did not affect clinical care. The study was conducted in accordance with the Declaration of Helsinki and its subsequent revisions.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}